|Description||In vitro, the IC50 for growth inhibition is approximately 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three- to fourfold in nude mice. siRNA against PPARgamma and a pharmacological antagonist demonstrated that functional PPARgamma was required for growth inhibitory activity of RS5444. RS5444 upregulated the cell cycle kinase inhibitor, p21WAF1/CIP1. RS5444inhibited culture growth and caused irreversible G1 arrest, but did not induce apoptosis. In addition, RS5444 caused dramatic changes in cellular morphology which were associated with increased motility and diminished cellular adherence, but no increase in the ability of such cells to digest and invade Matrigel. Treatment with RS5444 leads to the up-regulation of RhoB and subsequent activation of p21, and that silencing of RhoB by RNAi blocks the ability of RS5444 to induce p21 and to inhibit ATC cells proliferation. The median peak efatutazone blood level was 8.6 ng/mL for 0.15-mg dosing vs 22.0 ng/mL for 0.3-mg twice daily dosing. Although efatutazone treatment did not reduce percentage of mice developing invasive cancer, it significantly reduced prevalence of noninvasive cancer and total number of cancers per mouse and increased prevalence of well-differentiated cancer subtypes not usually seen in this mouse model.|
|Synonyms||Efatutazone; CS-7017; RS5444; CS 7017; RS 5444|
PT-S58 is a full peroxisome proliferator-activated receptor (PPAR) β/δ antagonist as a derivative of GSK0660. But PT-S58 has a three-fold higher affinity for th...
GW501516 is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. Phase 4.
GW9662 is a potent, irreversible and selective PPARgamma antagonist, which prevented activation of PPARgamma and inhibited growth of human mammary tumour cell ...
GW0742 is a potent and highly selective PPARβ/δ agonist, with IC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ.
SR 1664 is a PPARγ (peroxisome proliferator-activated receptor γ ) inhibitor. SR 1664 can block PPARγ by cyclin-dependent kinase 5 with an IC50 value of 80 nM a...
Muraglitazar is a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist(EC50s = 320 and 110 nM in vitro).
BM152054, a thiazolidinedione, revealed to be potent PPARg-activators in transient transfection assays in vitro.
The dihydrochloride salt form of DG-172, a piperazin drrivative, is a PPARβ/δ inverse agonist that could promote cell differentiation of dendritic induced by GM...
MHY 908 is a dual PPARα/γ agonist and a melanogenesis inhibitor that suppresses mushroom tyrosinase activity (IC50 value 8.19 μM). MHY908 exhibits more potent a...
Aleglitazar is a potent dual agonist of peroxisome proliferator-activated receptor (PPAR) α/γ.
MCC-555, a thiazolidinedion derivative, has been found to be a PPAR agonist that was once studied as hyperglycaemic and hyperlipidaemic. The Phase II trial agai...
T0070907 was identified as a potent and selective PPARgamma antagonist. T0070907 blocked PPARgamma function in both cell-based reporter gene and adipocyte diffe...
ST247 is a selective and inverse peroxisome proliferator-activated receptor (PPAR)β/δ agonist with IC 50 value of 19 nm, 10-fold more potent than GSK0660 with I...
CS-7017 monohydrate is a peroxisome proliferator activated receptor gamma (PPAR) agonist. It is a potential therapy for thyroid cancer and liposarcoma. It is al...
Pemafibrate is a Peroxisome proliferator-activated receptor alpha agonist. It can decrease the secretion of inflammatory markers without affecting cell prolifer...
Troglitazone, PPARγ agonist, is an anti-diabetic thiazolidinedione (TZD) with anti-inflammatory and anti-tumor activity, which was approved for the treatment of...
WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.
GW-9820 is a PPAR-gamma agonist with potential antidiabetic effect.
Rosiglitazone exhibits insulin-sensitising activity 60- to 200-fold higher than that of troglitazone, englitazone, or piogliazone in rodent models of insulin re...
Imiglitazar, also known as TAK-559，with hypoglycemic activity it is a non-thiazolidinedione dual peroxisome proliferator-activated receptor (PPAR) alpha and gam...